BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 32635810)

  • 1. Successful oxaliplatin desensitization protocol in a patient with colorectal metastatic cancer.
    de Lira-Quezada CE; Villarreal-Gonzalez RV; Gonzalez-Diaz SN; Carrasco-Diaz LL
    J Oncol Pharm Pract; 2021 Mar; 27(2):490-493. PubMed ID: 32635810
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypersensitivity reactions to oxaliplatin: a retrospective study and the development of a desensitization protocol.
    Syrigou EI; Karapanagiotou EM; Alamara CV; Boura PG; Saif MW; Syrigos KN
    Clin Colorectal Cancer; 2009 Apr; 8(2):106-9. PubMed ID: 19739272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Desensitization to oxaliplatin with two stages of premedication in a patient with metastatic rectal cancer.
    Nozawa H; Muto Y; Yamada Y
    Clin Ther; 2008 Jun; 30(6):1160-5. PubMed ID: 18640472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypersensitivity reactions to oxaliplatin and the application of a desensitization protocol.
    Gammon D; Bhargava P; McCormick MJ
    Oncologist; 2004; 9(5):546-9. PubMed ID: 15477639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypersensitivity Reactions to oxaliplatin: incidence and management.
    Gowda A; Goel R; Berdzik J; Leichman CG; Javle M
    Oncology (Williston Park); 2004 Nov; 18(13):1671-5; discussion 1676, 1680, 1683-4. PubMed ID: 15648298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oxaliplatin hypersensitivity: case report and successful repeat desensitization.
    Edmondson DA; Gruling BJ; Urmanski AM; Wong SJ; Levy MB
    Am J Ther; 2007; 14(1):116-8. PubMed ID: 17303980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does Rapid Drug Desensitization to Chemotherapy Affect Survival Outcomes?
    Berges-Gimeno MP; Carpio-Escalona LV; Longo-Muñoz F; Bernal-Rubio L; Lopez-Gonzalez P; Gehlhaar P; Pachon V; Ferreiro-Monteagudo R; Madrigal-Burgaleta R; Alvarez-Cuesta E
    J Investig Allergol Clin Immunol; 2020; 30(4):254-263. PubMed ID: 31188129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new non-dilution rapid desensitization protocol successfully applied to all-grade platinum hypersensitivity.
    Chung SJ; Kang SY; Kang RY; Kim YC; Lee KH; Kim TY; Han SW; Kang HR
    Cancer Chemother Pharmacol; 2018 Nov; 82(5):777-785. PubMed ID: 30105458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delayed hypersensitivity to oxaliplatin in a nigerian patient with colorectal cancer-A case report.
    Aliyu UM; Okwonna CO
    J Oncol Pharm Pract; 2021 Jul; 27(5):1258-1260. PubMed ID: 33131450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complete metabolic response after carboplatin desensitization in Peritoneal Carcinomatosis.
    Villarreal-González RV; González-Díaz SN; Vidal-Gutiérrez O; Zayas-Villanueva OA; Solís-Lara H; Santos-Fernández WJ; Casas-Murillo CA; López-Méndez A
    J Oncol Pharm Pract; 2022 Sep; 28(6):1441-1445. PubMed ID: 35119322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypersensitivity reactions to oxaliplatin: a case report and the success of a continuous infusional desensitization schedule.
    Lim KH; Huang MJ; Lin HC; Su YW; Chang YF; Lin J; Chang MC; Hsieh RK
    Anticancer Drugs; 2004 Jul; 15(6):605-7. PubMed ID: 15205605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypersensitivity reactions to oxaliplatin in two asian patients.
    Ng CV
    Ann Pharmacother; 2005 Jun; 39(6):1114-8. PubMed ID: 15886290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypersensitivity Reactions to Oxaliplatin: Identifying the Risk Factors and Judging the Efficacy of a Desensitization Protocol.
    Okayama T; Ishikawa T; Sugatani K; Yoshida N; Kokura S; Matsuda K; Tsukamoto S; Ihara N; Kuriu Y; Nakanishi M; Nakamura T; Kamada K; Katada K; Uchiyama K; Takagi T; Handa O; Konishi H; Yagi N; Naito Y; Otsuji E; Hosoi H; Miki T; Itoh Y
    Clin Ther; 2015 Jun; 37(6):1259-69. PubMed ID: 25862137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful desensitization to oxaliplatin.
    Mis L; Fernando NH; Hurwitz HI; Morse MA
    Ann Pharmacother; 2005 May; 39(5):966-9. PubMed ID: 15784807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oxaliplatin: Detection and Management of Hypersensitivity Reactions.
    Rogers BB; Cuddahy T; Briscella C; Ross N; Olszanski AJ; Denlinger CS
    Clin J Oncol Nurs; 2019 Feb; 23(1):68-75. PubMed ID: 30682002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypersensitivity Reaction and Rapid Drug Desensitization with Chemotherapeutics: A Tertiary Reference Center Experiences.
    Bulut İ; Yegin Katran Z
    Int Arch Allergy Immunol; 2023; 184(9):849-855. PubMed ID: 37442106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful rechallenge for oxaliplatin hypersensitivity reactions in patients with metastatic colorectal cancer.
    Yanai T; Iwasa S; Hashimoto H; Kato K; Hamaguchi T; Yamada Y; Shimada Y; Yamamoto H
    Anticancer Res; 2012 Dec; 32(12):5521-6. PubMed ID: 23225461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid desensitization to brentuximab vedotin after severe anaphylaxis in the treatment of refractory Hodgkin's lymphoma.
    V Villarreal-Gonzalez R; N Gonzalez-Diaz S; E de Lira-Quezada C; Gómez-Almaguer D; Gómez-De León A; Acuña-Ortega N
    J Oncol Pharm Pract; 2021 Mar; 27(2):505-508. PubMed ID: 32686619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Type II hypersensitivity reactions after oxaliplatin rechallenge can be life threatening.
    Vyskocil J; Tucek S; Kiss I; Fedorova L; Nevrlka J; Zdrazilova-Dubska L
    Int Immunopharmacol; 2019 Sep; 74():105728. PubMed ID: 31288153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful desensitization protocol for hypersensitivity reactions caused by oxaliplatin.
    Rosique-Robles D; Vicent Verge JM; Borrás-Blasco J; Giner-Marco V; Casterá E; Galan-Brotons A; Abad J
    Int J Clin Pharmacol Ther; 2007 Nov; 45(11):606-10. PubMed ID: 18077926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.